{"entity":{"id":"nct05229497","kind":"trial","name":"A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors","aka":[],"tldr":"A phase 1/2 trial of AK117, Carboplatin, Cisplatin and Gemcitabine in advanced solid tumours, run by Akeso, active and no longer recruiting.","summary":"A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors is a phase 1/2 interventional study registered as NCT05229497 by Akeso, with 154 participants enrolled, started 2022-05-04 and due to reach its primary completion in 2026-12-31. Interventions recorded: AK112, AK117, Carboplatin, Cisplatin, 5-Fluorouracil and Gemcitabine.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05229497","url":"https://clinicaltrials.gov/study/NCT05229497"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["ak117","carboplatin","cisplatin","gemcitabine"],"companies":["akeso"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05229497","phase":"1/2","setting":"A Phase Ib/II Study of AK112#PD-1/VEGF Bispecific Antibody# in Combination With AK117#Anti-CD47 Antibody# in Advanced Malignant Tumors","sponsor":"Akeso","enrolled":154,"outcomes":[]},"route":"/trials/nct05229497/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"ak117","kind":"drug","name":"AK117","route":"/drugs/ak117/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"}],"company":[{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/"}]}}